Latest Chronic kidney disease Stories

Protecting Kidneys With Fruits, Vegetables

2013-02-08 11:44:23

Dietary changes reduce metabolic acidosis and kidney injury in kidney disease patients Highlight: -Adding fruits and vegetables to the diet is an effective alternative to medication to reduce metabolic acidosis and kidney injury in late-stage chronic kidney disease. -Metabolic acidosis is a common complication of kidney disease. Adding fruits and vegetables to the diet may help protect the kidneys of patients with chronic kidney disease (CKD) with too much acid build-up, according...

Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET

2013-02-08 08:25:55

NEW YORK, Feb. 8, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the 15th Annual BIO CEO & Investor Conference, being held February 11-12, 2013, in New York City. Mr. Bentsur's presentation is scheduled to take place on Monday, February 11(th), at 2:30 PM ET. A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page...

EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs in the Haemodialysis Patient Population

2013-02-07 08:25:44

EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' study, ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, of 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts: (Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)...

EU5 Nephrologists Report a Stabilization of Phosphate Binder Treatment Prevalence in the Late-Stage CKD and Dialysis Patient Populations

2013-02-05 08:36:15

EXTON, Penn., Feb. 5, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds the following key results, according to a recent BioTrends' report, ChartTrends: Bone and Mineral Metabolism in Chronic Kidney Disease - Non-Dialysis (CKD-ND) and Dialysis, which contains data from 962 EU5 dialysis patient charts and 928 EU5 CKD-ND patient charts: On average, nephrologists in the EU5 countries...

NxStage Home Hemodialysis Patient Awareness Tour Kicks Off January 29th

2013-01-28 08:29:22

LAWRENCE, Mass., Jan. 28, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced today that NxStage patient advocate Jim Smith, 64, of Indianola, Washington is beginning the first NxStage Home Hemodialysis Patient Awareness Tour of 2013 with a 4-week journey starting January 29th. (Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO ) The Tour is designed to increase patient awareness of home...

Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to Discuss Top-Line Results from Zerenex(TM) Phase 3 Long-Term Study

2013-01-27 20:20:16

NEW YORK, Jan. 27, 2013 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) will host a conference call tomorrow, Monday, January 28, at 8:00am ET to review the top-line results from the Phase 3 long-term study component of its Phase 3 registration program of Zerenex((TM)) (ferric citrate), the Company's ferric iron-based phosphate binder for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis. Keryx...

DSI Lyman Dialysis Clinic Opens Doors to Greenville Area Dialysis Patients

2013-01-21 20:21:01

LYMAN, S.C. and GREENVILLE, S.C., Jan. 21, 2013 /PRNewswire/ -- DSI Renal, a leading provider of dialysis services for patients suffering from chronic kidney failure, today announced the opening of its new DSI Lyman Dialysis clinic in Lyman, South Carolina. The clinic will host an open house on Tuesday, January 22, from 5 pm to 8 pm ET for patients, physicians, media and other visitors interested in seeing the state-of-the-art new facility. The open house event will include a...

Pentec Health Granted UK Patent for PROPLETE®

2013-01-15 23:03:57

Patent is a First in Europe, Expands Global Market for Pentec Philadelphia, Pennsylvania (PRWEB) January 15, 2013 In a move to expand its geographic reach to international markets and further implement the strategic growth plan of the company, Pentec Health, Inc. today announced that it has been awarded a patent by the Intellectual Property Office of the United Kingdom for its speciality pharmacy compounded prescription renal formulation, PROPLETE®. Pentec’s geographic expansion is...

Drug Fails To Help Kidney Transplant Recipients

2013-01-11 13:19:05

Results come from large, randomized, placebo-controlled trial Highlight: -While safe and well-tolerated, angiotensin II blockade did not lessen tissue scarring or prevent kidney failure in kidney transplant recipients. -Angiotensin II blockade is known to slow kidney disease progression in individuals without transplants. A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to...

OPKO Health to acquire privately held Cytochroma

2013-01-08 20:21:23

Acquisition Includes Replidea(TM) and Alpharen(TM), Both in Phase 3 Clinical Trials with Kidney Disease Patients MARKHAM, ON, Jan. 8, 2013 /PRNewswire/ - Cytochroma today announced that it has entered into a definitive agreement with OPKO Health, Inc. (NYSE:OPK) under which Cytochroma, a privately held pharmaceutical company with operations in Markham, ON and Bannockburn, IL, will be acquired by OPKO. Through this transaction, OPKO will acquire worldwide rights to Cytochroma's two...